SANDOZ 618 (Rivastigmine Tartrate 1.5 mg)
Pill with imprint SANDOZ 618 is Yellow, Capsule-shape and has been identified as Rivastigmine Tartrate 1.5 mg. It is supplied by Sandoz Pharmaceuticals Inc.
Rivastigmine is used in the treatment of parkinson's disease; alzheimer's disease and belongs to the drug class cholinesterase inhibitors. There is no proven risk in humans during pregnancy. Rivastigmine 1.5 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for SANDOZ 618
Rivastigmine Tartrate
- Imprint
- SANDOZ 618
- Strength
- 1.5 mg
- Color
- Yellow
- Size
- 18.00 mm
- Shape
- Capsule-shape
- Availability
- Prescription only
- Drug Class
- Cholinesterase inhibitors
- Pregnancy Category
- B - No proven risk in humans
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Sandoz Pharmaceuticals Inc.
- National Drug Code (NDC)
- 00781-2614 (Discontinued)
- Inactive Ingredients
-
gelatin,
hypromelloses,
magnesium stearate,
microcrystalline cellulose,
ferric oxide red,
silicon dioxide,
titanium dioxide,
ferric oxide yellow
Note: Inactive ingredients may vary.
More about rivastigmine
- Side effects
- Drug interactions
- Dosage information
- During pregnancy
- Reviews (34)
- Drug images
- Pricing & coupons
- Drug class: cholinesterase inhibitors
Patient resources
- Drug Information
- Rivastigmine transdermal
- Rivastigmine (Advanced Reading)
- Rivastigmine Transdermal (Advanced Reading)
- Rivastigmine Capsules
- Other brands
- Exelon
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.